The association between statin therapy during intensive care unit stay and the incidence of venous thromboembolism: a propensity score-adjusted analysis
| Autor: | Yaseen M. Arabi, Asgar H. Rishu, Haytham Tlayjeh, Hasan M. Al-Dorzi, Shmeylan Al Harbi, Mohammad K. Khedr |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Risk
medicine.medical_specialty Critical Care Hospital mortality Critical Illness Saudi Arabia Kaplan-Meier Estimate law.invention Cohort Studies Propensity scores law Thromboembolism Internal medicine Intensive care Clinical endpoint Humans Medicine Pharmacology (medical) Prospective Studies cardiovascular diseases Propensity Score Intensive care medicine Prospective cohort study Aged Proportional Hazards Models Pharmacology business.industry Incidence Incidence (epidemiology) Hazard ratio Statins Length of Stay Middle Aged Intensive care unit Outcome assessment Intensive Care Units Propensity score matching Hydroxymethylglutaryl-CoA Reductase Inhibitors business Research Article Venous thromboembolism Cohort study |
| Zdroj: | BMC Pharmacology & Toxicology |
| ISSN: | 2050-6511 |
| DOI: | 10.1186/2050-6511-14-57 |
| Popis: | Background Studies have shown that statins have pleiotropic effects on inflammation and coagulation; which may affect the risk of developing venous thromboembolism (VTE). The objective of this study was to evaluate the association between statin therapy during intensive care unit (ICU) stay and the incidence of VTE in critically ill patients. Methods This was a post-hoc analysis of a prospective observational cohort study of patients admitted to the intensive care unit between July 2006 and January 2008 at a tertiary care medical center. The primary endpoint was the incidence of VTE during ICU stay up to 30 days. Secondary endpoint was overall 30-day hospital mortality. Propensity score was used to adjust for clinically and statistically relevant variables. Results Of the 798 patients included in the original study, 123 patients (15.4%) received statins during their ICU stay. Survival analysis for VTE risk showed that statin therapy was not associated with a reduction of VTE incidence (crude hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.28-1.54, P = 0.33 and adjusted HR 0.63, 95% CI 0.25-1.57, P = 0.33). Furthermore, survival analysis for hospital mortality showed that statin therapy was not associated with a reduction in hospital mortality (crude HR 1.26, 95% CI 0.95-1.68, P = 0.10 and adjusted HR 0.98, 95% CI 0.72-1.36, P = 0.94). Conclusion Our study showed no statistically significant association between statin therapy and VTE risk in critically ill patients. This question needs to be further studied in randomized control trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|